PMID- 19642466
OWN - NLM
STAT- MEDLINE
DCOM- 20090915
LR  - 20151119
IS  - 0370-629X (Print)
IS  - 0370-629X (Linking)
VI  - 64
IP  - 5-6
DP  - 2009 May-Jun
TI  - [Omralizumab (Xolair) in severe persistent allergic asthma].
PG  - 313-7
AB  - Asthma is a chronic inflammatory airways disease. The inflammatory process is in 
      many patients driven by an immunoglobulin E (IgE)-dependent process. Patients 
      with severe asthma are at high risk of serious exacerbations and death and have 
      few therapeutic options available. Omalizumab is a humanized monoclonal antibody 
      that acts by binding to and inhibiting the effects of IgE, thereby interfering 
      with one aspect of the asthma cascade. In addition to decreasing exacerbations, 
      it has a steroid sparing role and many beneficial effects in asthma. As suggested 
      by the new asthma GINA 2006 guidelines, this biological agent is indicated in 
      severe persistent allergic asthma.
FAU - Schleich, F
AU  - Schleich F
AD  - Service de Pneumologie, CHU de Liege, Belgique.
FAU - Manise, M
AU  - Manise M
FAU - Louis, R
AU  - Louis R
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - L'omalizumab (Xolair) dans le traitement de l'asthme allergique persistant 
      severe.
PL  - Belgium
TA  - Rev Med Liege
JT  - Revue medicale de Liege
JID - 0404317
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 2P471X1Z11 (Omalizumab)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Anti-Asthmatic Agents/*therapeutic use
MH  - Antibodies, Anti-Idiotypic
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Asthma/*drug therapy
MH  - Humans
MH  - Immunoglobulin E/immunology
MH  - Omalizumab
MH  - Severity of Illness Index
EDAT- 2009/08/01 09:00
MHDA- 2009/09/16 06:00
CRDT- 2009/08/01 09:00
PHST- 2009/08/01 09:00 [entrez]
PHST- 2009/08/01 09:00 [pubmed]
PHST- 2009/09/16 06:00 [medline]
PST - ppublish
SO  - Rev Med Liege. 2009 May-Jun;64(5-6):313-7.